Embody Biosciences
Embody Biosciences is a private biotech that builds a brain health and neurodegeneration digital twin platform, combining causal computational systems physiology modeling and Bayesian machine learning to support biopharmaceutical R&D and academic precision medicine research through partnerships.
- Company typePrivate
- Founded2020
- HeadquartersCorte Madera, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Embody Biosciences does
Embody Biosciences (operating as EmbodyBio) is a private biotechnology company founded in 2020 that builds computational tools for brain health and neurodegenerative disease research. The company's core product is the Brain Health & Neurodegeneration Digital Twin Platform, a unified offering that combines a Causal Computational Systems Physiology Model, Bayesian Machine Learning, multiomic data mining and integration (genomics, proteomics, metabolomics), risk assessment and decision-analytic tooling, and individual-patient mechanism of action (MoA) assessment for translational and clinical analysis.
The platform serves two primary customer segments: biopharmaceutical companies conducting drug discovery and development for neurodegenerative diseases, and academic research institutions working in multiomic data science and precision health/medicine. Its go-to-market is partnership-driven rather than broad direct sales — the company explicitly states it is 'Partnering with industry and academic leaders in multiomic data science, precision health/medicine, and neurodegenerative biopharmaceutical R&D,' with inbound engagement handled through a direct email contact point ([email protected]). No pricing model, public customers, contract structures, or revenue figures are disclosed.
The company is co-founded and led by Thomas Paterson (Co-Founder & CEO) and Jennifer Craig (Co-Founder & Director of Modeling), and operates with a 1–10 employee headcount. No funding rounds, investors, customers, awards, patents, regulatory milestones, or geographic operating data are publicly disclosed. The website (embody.bio) is the primary commercial touchpoint, and the platform is presented as a single integrated product rather than a modular suite. Evidence of installed base, recurring revenue, or commercial traction is not available in the source material.
Embody Biosciences firmographics
Firmographics- Name
- Embody Biosciences
- Website
- https://embody.bio
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Embody Biosciences is a private biotech that builds a brain health and neurodegeneration digital twin platform, combining causal computational systems physiology modeling and Bayesian machine learning to support biopharmaceutical R&D and academic precision medicine research through partnerships.
- Ownership category
- akta.pro rank
Embody Biosciences industry classification
Industry- Product category
- Computational Biology Software
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
Keywords
Where Embody Biosciences is headquartered
LocationHeadquarters
- HQ city
- Corte Madera
- HQ country
- United States
- HQ region
- North America
Markets served
Embody Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Embody Biosciences product offering
Product offeringCore offering
EmbodyBio provides a Brain Health & Neurodegeneration Digital Twin Platform that integrates a Causal Computational Systems Physiology Model with Bayesian Machine Learning and multiomic data mining to deliver individual-patient mechanism of action assessment, risk assessment, and decision-analytic tools. The platform is offered to biopharmaceutical R&D teams and academic research institutions working on neurodegenerative disease and precision health/medicine applications.
Product overview
EmbodyBio's primary offering is a Brain Health & Neurodegeneration Digital Twin Platform that integrates causal computational systems physiology modeling, Bayesian machine learning, multiomic data mining, and risk assessment tools. The platform serves both precision health/medicine applications and biopharmaceutical R&D, providing individual-patient mechanism of action assessment for translational and clinical analysis. It functions as a single unified platform rather than a modular product suite.
Differentiator
Problem solved
Functional benefit
Products and services
- Brain Health & Neurodegeneration Digital Twin Platform
Companies that use Embody Biosciences
Customer profileSegments2 records
Ideal customer profiles2 records
Embody Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
Embody Biosciences partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights4 records
Embody Biosciences competitors and assessment
Company assessmentDirect peers
- GNS Healthcare: Applies causal AI and Bayesian machine learning to multiomic and clinical data for biopharma R&D and precision medicine — closely aligned with EmbodyBio's causal computational physiology + Bayesian ML + multiomic integration approach.
- Insilico Medicine: AI-driven drug discovery company with explicit focus on neurodegeneration and aging-related diseases; competes for the same biopharma R&D budget targeting brain health using computational/AI methods analogous to EmbodyBio.
- CytoReason: AI multi-omics platform for biopharma R&D that integrates genomics, proteomics, and other omics for disease modeling — directly comparable to EmbodyBio's multiomic mining and integration capability for translational analysis.
- Unlearn.AI: Develops AI-based digital twin technology primarily for clinical trials and personalized prognosis — directly overlapping with EmbodyBio's digital twin platform concept applied to biopharma R&D and individual-patient analysis.
- InSilicoTrials: Cloud-based in silico trial and digital twin/simulation platform for pharmaceutical R&D — directly comparable in offering digital twin-style modeling tools to biopharma sponsors.
Emerging players
- Lantern Pharma: AI-driven precision oncology company using genomic biomarker data for drug development — comparable business model of AI/data-driven R&D services and platform licensing to pharma.
- Aria Pharmaceuticals: AI-first biopharma focused specifically on neurodegeneration and age-related disease drug discovery — overlaps in therapeutic focus and in applying AI/causal methods to brain health R&D.
- Quris-AI: AI-driven platform combining patient-on-a-chip and machine learning for drug safety and efficacy prediction — comparable in using AI/ML plus biology-informed modeling for biopharma R&D applications.
Broad incumbents
- Recursion Pharmaceuticals: Large-scale AI/ML-enabled drug discovery platform spanning multiple therapeutic areas — competes for biopharma partnership budgets and platform-licensing deals against specialized players like EmbodyBio.
- SOPHiA Genetics: Established AI-driven genomics/multi-omic data analysis platform sold to hospitals and research institutions — comparable as a broader incumbent in AI-based multiomic analysis and precision medicine.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Embody Biosciences social profiles
Digital presenceEmbody Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Embody Biosciences leadership team
Management profileNumber of profiles
Profiles2 records
Embody Biosciences funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Embody Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Embody Biosciences
What does Embody Biosciences do?
EmbodyBio provides a Brain Health & Neurodegeneration Digital Twin Platform that integrates a Causal Computational Systems Physiology Model with Bayesian Machine Learning and multiomic data mining to deliver individual-patient mechanism of action assessment, risk assessment, and decision-analytic tools. The platform is offered to biopharmaceutical R&D teams and academic research institutions working on neurodegenerative disease and precision health/medicine applications.
When was Embody Biosciences founded?
Embody Biosciences was founded in 2020. It employs 1 to 10 people.
Where is Embody Biosciences based?
Embody Biosciences is headquartered in Corte Madera, United States, in the North America region.
Who are Embody Biosciences's main competitors?
Direct peers on record are GNS Healthcare, Insilico Medicine, CytoReason, Unlearn.AI and InSilicoTrials. Emerging players are Lantern Pharma, Aria Pharmaceuticals and Quris-AI. Broad incumbents are Recursion Pharmaceuticals and SOPHiA Genetics.
Does Embody Biosciences have an API?
No public API is recorded for Embody Biosciences.
What industry is Embody Biosciences in?
Embody Biosciences's product category is Computational Biology Software. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 54171 and its SIC code is 8731.